US 12,077,589 B2
Fusion protein of interferon (IFN) and anti-PD-L1 antibody and use thereof
Yangxin Fu, Beijing (CN); Yong Liang, Beijing (CN); and Hua Peng, Beijing (CN)
Assigned to INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES, Beijing (CN)
Appl. No. 17/048,106
Filed by INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES, Beijing (CN)
PCT Filed Apr. 12, 2019, PCT No. PCT/CN2019/082360
§ 371(c)(1), (2) Date Oct. 16, 2020,
PCT Pub. No. WO2019/201161, PCT Pub. Date Oct. 24, 2019.
Claims priority of application No. 201810336178.1 (CN), filed on Apr. 16, 2018.
Prior Publication US 2021/0147548 A1, May 20, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/555 (2006.01); C07K 14/56 (2006.01); C07K 14/565 (2006.01); C07K 14/57 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/555 (2013.01); C07K 14/56 (2013.01); C07K 14/565 (2013.01); C07K 14/57 (2013.01); C07K 16/2818 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01)] 11 Claims
 
1. A fusion protein, wherein, the fusion protein is IFN-anti-PD-L1 formed by fusion of an interferon (IFN) and a PD-L1 binding protein and the fusion protein is a heterodimer protein, the fusion protein comprises a first polypeptide and a second polypeptide,
wherein the first polypeptide and the second polypeptide are different, and the first polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 1, and the second polypeptide comprises an Ig Fc region and an IFN located at a N-terminus of the Ig Fc region, wherein, an Fc region in the first polypeptide and the Ig Fc region in the second polypeptide are Igs of the same subtype and, wherein
the IFN is selected from the group consisting of a type I IFN, a type I IFN mutant, a type II IFN and a type III IFN, wherein the type III IFN is IFN-α, IFN-β, IFN-γ, IFN-λ1 (IL-29), IFN-λ2 (IL-28a), IFN-λ (IL-28b) or IFN-ω; and the IFN is derived from human or mice.